Table 1.
Characteristics of the Phase III Trial Children (5–17 months)
| Variable | Categorical: N (%), Numerical: Median (IQR) | ||
|---|---|---|---|
| Ghana (N = 992) | Malawi (N=771) | Gabon (N = 664) | |
| Sex | |||
| Female | 483 (48.7%) | 383 (49.7%) | 307 (46.2%) |
| Male | 509 (51.3%) | 388 (50.3%) | 357 (53.8%) |
| Age at Vaccination Series Completion (Days) | |||
| Median (IQR) | 461 (333.5, 539) | 411.5 (316, 502.75) | 385 (270.5, 495.5) |
| Min - Max | 216–724 | 211–700 | 197–636 |
| Missing | 9 | 9 | 13 |
| Vaccine Status | |||
| RTSS/AS01 (4 dose) | 332 (33.5%) | 253 (32.8%) | 218 (32.8%) |
| RTS,S/AS01 (3 dose) | 330 (33.3%) | 263 (34.1%) | 223 (33.6%) |
| Control | 330 (33.3%) | 255 (33.1%) | 223 (33.6%) |
| Estimated Malaria Transmission Intensity (Cases per Person-Year) | |||
| Median (IQR) | 2.30 (1.69, 2.81) | 0.24 (0.18, 0.32) | 0.30 (0.15, 0.50) |
| Min - Max | 0.85–4.45 | 0.08–2.47 | 0.04–0.92 |
| Missing | 4 | 1 | 134 |
| Parasitemia during the Vaccination Series | |||
| Yes | 230 (23.2%) | 37 (4.8%) | 26 (3.9%) |
| No | 762 (76.8%) | 734 (95.2%) | 638 (96.1%) |